The stock of AgeX Therapeutics, Inc. (NYSE:AGE) is now priced at $1.52 and the shares are 0.42 points up or 38.18% higher compared to its previous closing price of $1.1. The stock had 4.059 million contracts set over the past session. AGE shares’ daily volume is compared to its average trading volume at 501448 shares. However, it has a float of 21.04 million and although its performance was 23.58% over the week, it’s one to watch. It means the stock’s downside potential is -100% with the AGE share price recently placing at $1.1 to $1.62. However, some brokerage firms have priced the stock below the average.
The shorts are running away from the AgeX Therapeutics, Inc. stock, with the latest data on short interest released on July 31, 2020, showing that short interest numbers in the AGE shares have declined. Short interest in the stock represents just 6.81% of its float, but the volume has dropped by 0. The average intraday trading volume has been shares, which means that days to cover moved to roughly.
In the last trading session, AgeX Therapeutics, Inc. (NYSE:AGE) raised by $0.29 over the week and gained $0.6199 on its 20-day. The stock’s high in the recent session is lower when compared to its 52-week high of $3.14. The stock recorded its established 52-week high on 08/19/19.
Since 04/21/20, the stock has traded to a low of $0.666 at 128.23%, an encouraging piece of data likely to interest most investors out to exploit the stock’s recent surge. The stock has a beta allocation of 0. Being above 1 means that the stock’s volatility is higher than the market and traders are keenly watching it.
Looking at current readings, AgeX Therapeutics, Inc.’s two-week RSI is 67.51. This suggests that the stock is neutral at the moment and that AGE shares’ price movement remains stable. The stochastic readings are equally revealing at 43.81% meaning the AGE share price is currently in neutral territory.
The technical chart shows that the AGE stock will likely settle at between $1.7267 and $1.9333 per share. However, if the stock dips below $1.2067, then its market would become much weaker. Any downside could see the stock price sliding to levels as low as $0.8933.
Currently, the stock is trading in the red of MACD, with a reading of -0.0167. Investors always pay attention to any move above or below the zero-line, mainly because the indicator points to the position of the stock’s short-term average relative to its long-term measure. A MACD -a reading above the zero line means that the short-term is above the long-term average. This scenario implies that there is an upward momentum. The opposite is true when the MACD falls below the zero-line.
The average rating for the AGE equity is 1.92 and is currently gathering a bullish momentum. Of 13 analysts tracking AgeX Therapeutics, Inc. polled by Reuters, 2 rated AGE as a hold. The remaining 11 analysts were split evenly. However, the split wasn’t equal as a majority (11) rated it as a buy or strong buy. 0 analyst advised investors against buying the stock or to sell if they own any of the stock.